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or actual risk factors for bleeding. The annual incidence of
cerebrovascular accidents was 3.8% among 163 high-risk
patients assigned to OA treatment, and 4.5% among 39
patients given Aspirin treatment. Relative to expected annu-
al incidence rates, cerebrovascular risk in anticoagulated
patients was reduced by about 70%. Conclusions: Underuse
of OAs is still common in Italy, and much of it cannot be
explained by the concern for haemorrhage. Support and
training in the complex task of anticoagulation management
may help to extend this efficacious prophylactic therapy to
all patients who may benefit from it.
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Introduction
Atrial fibrillation (AF) is a common disorder of cardiac
rhythm and a strong, independent risk factor for stroke, as it
is associated with the formation of left atrial thrombi [1].
With advancing age, AF becomes an increasingly important
cause of stroke, as the prevalence of this arrythmia rises from
<1% in those less than 60 years old to 8%–10% in those
older than 80 [2–4].
Adjusted-dose warfarin was found to reduce the inci-
dence of stroke by about 60%, with absolute risk reductions
of 3% per year for primary prevention (referring to patients
without previous stroke or transient ischaemic attacks
(TIAs)) and 8% per year for secondary prevention (referring
to patients with previous stroke or TIA) [5–7]. In contrast,
Aspirin reduced the incidence of stroke by about 20%, with
absolute risk reductions of 1.5% per year for primary pre-
vention and 2.5% per year for secondary prevention [8].
When compared to Aspirin, warfarin – at a dose adjusted to
maintain an International Normalised Ratio (INR) of 2–3 –
reduced the risk by about 40%, with similar relative risk
Intern Emerg Med (2007) 2:24–28
DOI 10.1007/s11739-007-0005-2
D. Ferro • L. Loffredo • L. Polimeni • F. Violi
Underuse of oral anticoagulants in patients with nonvalvular
atrial fibrillation in Italy
ORIGINAL
Received: 24 July 2006 / Accepted in revised form: 30 October 2006 / Published online: 31 March 2007
Abstract Introduction: Oral anticoagulants (OAs) are sig-
nificantly more effective than Aspirin in the prevention of
cerebrovascular accidents among patients with atrial fibril-
lation (AF). Several studies, however, showed OAs to be
widely underused in these patients. Objective: To assess the
appropriateness of antithrombotic therapy in an Italian pop-
ulation of AF patients. Methods: Two hundred and fifty-five
consecutive patients affected by nonvalvular AF participat-
ed in the study. Data were collected on demographic char-
acteristics, risk factors for stroke, current prophylactic ther-
apy, and perceived or actual risk factors for bleeding. INR
levels were measured. Patients were stratified by their risk
for stroke (214 at high risk, 21 moderate, 20 low), and their
prophylactic therapy was analysed in light of international
antithrombotic therapy recommendations. After therapy
adjustment, 203 of our patients were followed-up for the
occurrence of cerebrovascular events for an average of 27
months. Results: Upon admission, 35% (n=75) of patients
in the high-risk category were either taking no antithrom-
botic prophylaxis or were being treated with Aspirin. In
addition, 38 of 139 patients receiving OAs had an INR<2.
Thus, a total of 113 (52.8%) high-risk subjects were not
receiving adequate antithrombotic therapy. Of high-risk
patients not treated with OAs, 46.7% reported no perceived
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reductions for primary and secondary prevention [9]; Aspirin
seems to be efficacious mainly in the prevention of smaller,
noncardioembolic strokes [1, 10].
Despite strong evidence in support of the clinical effica-
cy of oral anticoagulants (OAs), and the lack of contraindi-
cations to their use, underuse of these medications is quite
common. In fact, anticoagulants are given to less than 50%
of AF patients at highest risk for stroke [11–13].
The aim of this study was to evaluate the appropriateness
of antithrombotic therapy in an Italian population of AF
patients. To reach this objective, we stratified patients by
their risk for stroke, and analysed the therapy they were
receiving on admission, in light of international antithrom-
botic therapy recommendations for patients in their risk cat-
egory. Most patients were then followed up for the occur-
rence of stroke or TIA after therapy adjustment.
Methods
Two hundred and fifty-five eligible subjects were recruited,
between April 2001 and September 2005, among consecutive
patients admitted to the IV Division of Clinical Medicine due to
nonvalvular AF – paroxysmal, persistent or permanent (lasting >6
months). Exclusion criteria were: mitral stenosis, mitral valve pros-
thesis or severe mitral regurgitation, lone AF, cancer, liver or kidney
diseases, acute or chronic inflammatory disorders.
Of the 255 patients recruited, 191 (74.9%) had permanent or
persistent AF, and 64 (25.1%) had paroxysmal AF.
Upon admission, the clinical staff interviewed patients and
reviewed their medical charts. The following data were collected:
demographics; actual or perceived risk factors for bleeding or
thromboembolic events; curative and prophylactic treatment for
thromboembolic and ischaemic events.
In order to assess the correct anticoagulation required and the
quality of anticoagulation control, two INR measurements were
performed on each patient at baseline, one week apart.
Anticoagulation intensity was considered insufficient if INR was <2
on both occasions.
Patients were stratified by their risk for stroke into the three cat-
egories below [1]:
High risk: patients with previous TIA or cerebrovascular acci-
dent; patients aged ≥75 with diabetes or hypertension; patients with
clinical evidence of valve disease, heart failure, thyroid disease and
impaired left ventricular function.
Moderate risk: patients aged <65 with clinical risk factors: dia-
betes, hypertension, peripheral vascular disease, ischaemic heart
disease; patients >65 not in the high-risk group.
Low risk: patients aged <65 with no history of embolism,
hypertension, diabetes or other clinical risk factors.
For the three risk categories (n=255), we calculated the propor-
tions of patients by type of antithrombotic prophylaxis received on
admission (OAs, Aspirin, none), and the proportion of patients with
insufficient anticoagulation intensity.
Two hundred and three of the patients were also followed up for the
incidence of stroke or TIA, for an average of 27 months (range 6–36
months). Prophylactic therapy was reconsidered for all subjects
before the beginning of follow-up. During follow-up, OA doses
were regularly adjusted based on periodic INR measurements, to
maintain INR levels of 2–3. The occurrence of stroke was deter-
mined on the basis of clinical manifestations, and confirmed by
computed tomography.
Results
Clinical characteristics of the entire study population
(n=255) are reported in Table 1. Mean age was 72.6 years,
with 44.7% of subjects older than 75. Forty-seven percent
were male. Hypertension was the most frequently reported
risk factor for stroke (78.8%), followed by coronary artery
disease (31.8%), congestive heart failure (31.4%) and dia-
betes (16.1%); 24.3% of patients reported a history of stroke,
TIA or systemic embolic event.
About 73% of patients were receiving antihypertensive
treatment (one or more medication): diuretics (58.1%),ACE-
inhibitors (54.6%), calcium-antagonists (47.1%) and beta-
blockers (29.7%).
Of the 255 patients studied, 84% were stratified to the
high risk group, 8.2% to the moderate risk group and 7.8%
to the low risk group. Figure 1 shows prophylactic therapy
on admission by risk group: among patients at low risk,
34.5% were being treated with OAs, 41.5% were being treat-
ed with Aspirin and 24% were taking no medications.
Among patients at high risk, 65% (n=139) were being treat-
ed with OAs, but 38 of these subjects were insufficiently
anticoagulated (INR<2). In addition, 35% (n=75) of high-
Table 1 Patient characteristics (N=255)
Demographic characteristics Frequency (%)
Mean age (years±SD) 72.6±10.4
Age
†65 51 (20.0%)
66–75 90 (35.3%)
>75 114 (44.7%)
Gender
Male 120 (47.0%)
Female 135 (53.0%)
Clinical characteristics
Hypertension 201 (78.8%)
CAD/atherosclerosis 81 (31.8%)
CHF (LV dysfunction) 80 (31.4%)
Diabetes 41 (16.1%)
History of stroke, TIA or systemic embolus 62 (24.3%)
History of AMI 46 (18%)
History of DVT or PE 11 (4.3%)
Thyrotoxicosis 2 (0.8%)
Behavioural risk factors
Cigarette smoking 48 (18.8%)
Alcohol abuse 51 (20%)
CAD, coronary artery disease; CHF, congestive heart failure; LV,
left ventricular; TIA, transient ischaemic attack; DVT, deep vein
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risk patients were either not receiving prophylaxis (11.5%)
or were being treated with Aspirin (23.4%). Considering the
entire group of patients at high risk, 113 subjects (52.8%)
were not receiving adequate antithrombotic therapy.
Patients with persistent or permanent AF were more like-
ly to be treated with OAs than those with paroxysmal AF
(67% vs. 52%; p<0.05).
To explore possible reasons for not prescribing anticoag-
ulation therapy, we analysed data on perceived or actual risk
factors for bleeding among patients at high risk for stroke
who were not receiving OAs (n=75). Neuropsychological
impairment was reported in 36% of cases, risk of falling in
22.7%, a past bleeding episode in 16%, peptic ulcer in 12%
and a history of aneurysm in 4%. Almost 48% of patients
reported no risk factors for haemorrhage (Table 2).
Two hundred and three patients (95 males, 108 females,
mean age 71.9±10.73 years) participated in the follow-up.
Eighty-eight percent of them were stratified to the high-risk
category, 7% to the moderate-risk category and 5% to the
low-risk category.
We prescribed OAs to 163 of 178 followed-up high-risk
patients. The remaining 15, who had poor compliance for
OA, as well as all 14 moderate-risk patients and 10 of 11
low-risk patients, were given Aspirin. One low-risk patient
refused any treatment.
During follow-up, 14 of 163 patients on OA (8.6%) expe-
rienced a cerebrovascular accident (12 stroke, 2 TIA), with
an annual incidence of 3.8%, compared to 4 of 39 patients
treated with Aspirin (10.2% – 1 stroke, 3 TIA), with an annu-
al incidence of 4.5%. If the expected annual risk of cere-
brovascular accident among untreated AF patients at high
risk ranges between 8 and 12% [1], treatment with OAs
reduced it by up to 70%. In contrast, in patients with moder-
ate or low risk, whose expected annual risk of cerebrovascu-
lar event is 1%–4% [1], treatment with Aspirin did not seem
to affect the annual rate of ischaemic events.
Discussion
Our data indicate that an underuse of OAs may be detected
in 35% of high-risk patients in an Italian population with
nonvalvular AF.
Several AF trials have shown that OAs are highly effective
in the prevention of stroke and death caused by thromboem-
Table 2 Factors associated with perceived or actual risk of bleed-
ing among high-risk patients not receiving OA therapy (N=75)
Factor Frequency n (%)*
Neuropsychological impairment 27 (36.0)
Risk of falling 17 (22.7)
Past bleeding episode 12 (16.0)
Peptic ulcer disease 9 (12.0)
History of aneurysm 3 (4.0)
None of these factors 35 (46.7)
*Some patients reported more than one factor
Fig. 1Antithrombotic prophylaxis in AF patients
(%) by risk category
White boxes: oral anticoagulants;
Grey boxes: Aspirin;
Black boxes: no treatment.bolism. Based on these studies, guidelines for the use of OAs
in AF patients at risk of stroke (high- and moderate-risk cate-
gories) have been published and are widely accepted [14–19].
In clinical practice however, the actual use of anticoagu-
lation in patients at risk for stroke has been disappointingly
low. Despite great variability between studies, with appro-
priate antithrombotic therapy rates ranging from 15% to 79%
[13], in most studies, appropriate OA treatment is observed
only in about 50% of cases [19–23].
In a recent study covering a broad geographic cross sec-
tion of US hospitals, the overall proportion of warfarin use
was 54%, 25% were treated with Aspirin and 22% received
no medication [23]. Compared to these data, our study, per-
formed using similar risk stratifications, shows a more fre-
quent use of OAs. In fact, among our high-risk patients, 65%
were taking OAs, 23.4% were being treated with Aspirin and
only 11.5% were left untreated. Indeed, the use of OAs in AF
patients has increased in Italy in the past few years, possibly
thanks to the establishment of anticoagulation clinics in our
country, a fruit of efforts that began with the founding of the
Italian Federation of Centers for the Surveillance of
Anticoagulant Therapies in 1989 [24].
Yet OA treatment, even where given, is not always ade-
quate: in our study, 27.3% of patients treated with OAs on
admission had an INR<2, indicating insufficient anticoagu-
lation intensity. Taking together high-risk patients who were
not being treated with OAs, and those with insufficient anti-
coagulation intensity, 52.8% of our high-risk patients were
not receiving the treatment recommended by international
guidelines.
Several surveys have studied physicians’ barriers to pre-
scribing anticoagulant therapy. Practical barriers to the use of
OAs include the need for frequent blood testing for pro-
thrombin time and ongoing dose adjustments [25, 26].
Patient-related factors such as old age, perceived embolic
risk and perceived risk of haemorrhage have been repeatedly
found to influence decisions on OA treatment [27–30]. The
reluctance to prescribe dose-adjusted OAs to elderly patients
is of special concern in view of the fact that trials show these
patients benefit most from this therapy [31, 32]. Surveyed
physicians have reported withholding OA therapy based on
the belief that patients would refuse therapy or be noncom-
pliant. According to one survey, 79% of physicians cited a
lack of patient reliability as a contraindication to therapy [29].
In a clinical scenario depicting a patient with a history of
falls, 71% of physicians believed anticoagulation therapy
was contraindicated [28]. Finally, some physicians reported
difficulty in maintaining INR levels within the therapeutic
range [25, 33].
Our data show however, in agreement with a recent study
[23], that among high-risk patients not treated with OAs,
about one half report none of the factors associated with per-
ceived or actual risk factors for bleeding. This indicates that
much OA underuse may not be accounted for by a concern
for haemorrhage.
An interesting finding in this context is the fact that
paroxysmal AF patients seem to be significantly less likely to
be treated with OAs than patients with persistent or perma-
nent AF. This phenomenon, observed in our population as
well as in another recent report [23], may point to a tenden-
cy among some physicians to underestimate the risk of
stroke in paroxysmal AF – a risk that is similar to that of
patients with persistent or permanent AF.
These and other results, indicating that urban patients are
more likely to receive anticoagulant therapy compared to
rural subjects (58% vs. 47%), and that cardiologists tend to
prescribe it more often than noncardiologists (69% vs. 52%)
[21], suggest that support and training in the complex task of
anticoagulation management may help extend and improve
the use of OA prophylaxis in AF patients at risk of cere-
brovascular events.
At the start of follow-up, we reconsidered antithrombot-
ic therapy and assigned OAs to all but 15 patients at high risk
of cerebrovascular accident. After 27 months  of follow-up,
a correct use of OAs was able to reduce the risk of ischaemic
stroke by about 70%. These results are in agreement with
those of randomised, controlled trials showing that dose-
adjusted anticoagulation reduces the risk of ischaemic stroke
by about 68% in unselected patients with AF [5–7].
In contrast, among patients with moderate or low risk,
treatment with Aspirin did not seem to reduce the annual rate
of ischaemic events. This may be due to a limited capacity of
this type of treatment to prevent serious, cardioembolic
events, which are frequent in AF patients [1, 10].
The small number of subjects, especially in the low and
moderate risk categories, is a limitation of the present study.
Larger, multicentre studies will be needed to confirm our
findings, and help clarify the reasons underlying OA pre-
scription practices in Italy.
In conclusion, this study shows that about one half of
Italian AF patients at high risk for stroke either did not
receive OAs or were receiving insufficient anticoagulation.
Support and training in the complex task of anticoagulation
management, as well as improved communication between
all those involved – patients, physicians and OA centres –
may help offer AF patients better protection from cere-
brovascular accidents through correct prophylactic anticoag-
ulation therapy.
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